Serious Adverse Events and Laboratory Monitoring Regimens for Outpatient Parenteral Antimicrobial Therapy With Cefazolin and Ceftriaxone
Shawnalyn W Sunagawa, Sarah Arduser, Molly M Miller, Elizabeth Lyden, Melissa LeMaster, Nicolas Cortes-Penfield, Richard J Hankins, Scott J Bergman, Bryan T Alexander · 2023
Read Serious Adverse Events and Laboratory Monitoring Regimens for Outpatient Parenteral Antimicrobial Therapy With Cefazolin and Ceftriaxone by Shawnalyn W Sunagawa, Sarah Arduser, Molly M Miller, Elizabeth Lyden, Melissa LeMaster, Nicolas Cortes-Penfield, Richard J Hankins, Scott J Bergman, Bryan T Alexander (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10727193.txt.
Description
Shawnalyn Sunagawa and co-authors review safety monitoring for home infusion antibiotics in a 2023 study. Patients on outpatient intravenous cefazolin or ceftriaxone usually give blood weekly to catch side effects early. Counting serious therapy-linked events in their cohort, the team found only 2.7 events per thousand weekly lab sets. So little yield from weekly draws suggests a lighter testing schedule could be safe and reasonable for these two drugs, cutting patient burden and cost.
Catalog record
| CREATOR | Shawnalyn W Sunagawa, Sarah Arduser, Molly M Miller, Elizabeth Lyden, Melissa LeMaster, Nicolas Cortes-Penfield, Richard J Hankins, Scott J Bergman, Bryan T Alexander |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |